Letolizumab

DB19072InvestigationalProtein Based Therapies

Letolizumab is under investigation in clinical trial NCT02273960 (Study to Evaluate Safety and Efficacy in Adult Subjects With ITP).

Mechanism
Curator reviewed
Also known as
Immunoglobulin (synthetic light chain variable region fragment) fusion protein with immunoglobulin g (synthetic fc fragment), noncovalently linked dimer
Code names
BMS-986004

Resolves to

Compound
UNII449MIE2SD6CAS1450981-87-9
Targets
P29965CD40LG

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Letolizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In